drugset / Trial / NCT06661018

Effect Supplementation of COenzyme Q10 in Acute STEMI Underwent PPCI

NCT06661018

Completed 46 enrolled Universitas Diponegoro
RandomizedParallel-groupTriple-blindTreatment

Summary

Left ventricular remodeling can still occur after primary percutaneous coronary intervention (PCI). Global longitudinal strain (GLS) assessment has been used as a predictor of left ventricular remodeling. Coenzyme Q10 is known for its anti-inflammatory and antioxidant properties, which may help reduce cardiac remodeling. This study aims to determine the effect of CoQ10 administration after myocardial infarction as an adjunct to standard therapy on left ventricular remodeling, assessed through changes in GLS values. Researchers will compare Coenzyme Q10 to a placebo to see if Coenzyme Q10 has a greater effect on improving left ventricular GLS values in patients with ST-Elevation Myocardial Infarction undergoing primary percutaneous coronary intervention.

Timeline

Start
2024-01-28
Primary completion
2024-04-30
Completion
2024-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Coenzyme Q10 Other / unclassified 100 mg Oral